Individual Optmizaton of therapy. Graham R Foster Professor of Hepatology QMUL
|
|
|
- Raymond Bennett
- 5 years ago
- Views:
Transcription
1 Individual Optmizaton of therapy Graham R Foster Professor of Hepatology QMUL
2 Conflicts of Interest Speaker and consultancy fees received from AbbVie, BI, BMS, Gilead, Janssen, Roche, Merck, Novarts, Springbank, Achillion, Idenix
3 Optmisaton of Therapy The Theory The Practce The costs
4 Optmisaton of therapy Theory % SVR Duraton of therapy - weeks
5 Optmisaton of therapy Theory % SVR Duraton of therapy - weeks
6 Optmisaton of therapy Theory % SVR Duraton of therapy - weeks
7 Optmisaton of therapy Theory % SVR Duraton of therapy - weeks
8 100 Optmisaton of Therapy Theory Huge trial needed to distnguish a real difference % SVR Duraton of therapy - weeks
9 Optmisaton of Therapy Theory Shorter duratons of therapy are cheaper BUT They have a higher risk of relapse
10 Optmisaton of Therapy Theory 100 % SVR 50 Some patents respond to short duraton therapy Duraton of therapy - weeks
11 Optmisaton of Therapy Theory We could identfy patents who will beneft from short duraton therapy We can then treat them with short courses
12 Optmisaton of Therapy Theory We could identfy patents who will beneft from short duraton therapy We can then treat them with short courses In theory this should save money
13 Optmisaton of Therapy The Theory The Practce The costs
14 TURQUOISE-II: SVR12 rates in GT1 treatment-naive and experienced cirrhotc patents by HCV genotype D + RBV 12-week arm week arm SVR12, % Patents GT1a GT1b Poordad F, et al. N Engl J Med Online DOI: /NEJMoa
15 TURQUOISE-II: SVR12 rates in GT1 treatment-naive and experienced cirrhotc patents by HCV genotype SVR12, % Patents D + RBV 12-week arm No significant difference between 12 and 24 weeks License is for 24 weeks in G1a 24-week arm GT1a GT1b Poordad F, et al. N Engl J Med Online DOI: /NEJMoa
16 Sofosbuvir/ledipasvir ± RBV for 8 weeks vs 12 weeks in treatment-naive non-cirrhotc G1 HCV-infected patents Wk 0 Wk 8 Wk 12 Wk 20 Wk 24 LDV/SOF n=215 LDV/SOF + RBV n=216 LDV/SOF n=216 Stratfed by HCV subtype (1a or 1b) G1 treatment-naive patents without cirrhosis SVR12 SVR12 SVR12 SVR12 (%) SVR12 G1 treatment naive 202/ / /216 LDV/SOF LDV/SOF + RBV LDV/SOF 8 weeks 12 weeks Kowdley K.V, et al. NEJM 2014;370: weeks without RBV not statstcally inferior Without cirrhosis 8 weeks is the right duraton
17 Optmisaton of Therapy The Practce Properly powered, prospectve, randomised trial shows 8 weeks is equal to 12 weeks Is this widely used?
18 SVR achieved (n=251) 8 wks LDV/SOF (n=263) Patent dispositon TN, non-cirrhotc (n=895) SVR not achieved (n=3) SVR achieved (n=604) *21 patents were on 12 weeks of LDV/SOF + RBV 12 wks LDV/SOF ± RBV (n=632)* Real-world experience from the TRIO Network: Effectveness of 8- or 12-week LDV/SOF in treatment-naive, noncirrhotc, G1 SVR not achieved (n=6) 3 out of 4 patents received the long regimen Relapse 9 Death 0 LTFU 6 d/c 3 251/263 Curry M, et al. AASLD 2015, San Francisco. #1046
19 Patent dispositon TN, non-cirrhotc (n=895) Real-world experience from the TRIO Network: Effectveness of 8- or 12-week LDV/SOF in treatment-naive, noncirrhotc, G1 SVR12 by fibrosis SVR achieved (n=251) 8 wks LDV/SOF (n=263) SVR not achieved (n=3) SVR achieved (n=604) *21 patents were on 12 weeks of LDV/SOF + RBV Curry M, et al. AASLD 2015, San Francisco. # wks LDV/SOF ± RBV (n=632)* Relapse 9 Death 0 LTFU 6 d/c 3 SVR12 by duraton Relapse 6 Death 2 LTFU 16 d/c 4 251/ /632 SVR not achieved (n=6) SVR12(%) SVR12(%) 42/ 44 52/ 53 79/ / / / / 32 F0 F1 F2 F3 SVR12 by baseline viral load <6MM 6MM+ 8 weeks 12 weeks 144/ / /456 8/8 162/170
20 Optmisaton of Therapy The Practce Clinicians and patents are conservatve They do not like to take risks Persuading people to use shorter duratons will not be easy
21 Optmisaton of Therapy What about shorter treatments? Can we fnd predictors of response to short duraton therapy?
22 Optmisaton of Therapy Theory 100 % SVR 50 Some patents respond to short duraton therapy Duraton of therapy - weeks
23 102 G1 ± cirrhosis treated with grazoprevir 100 mg/elbasvir 50 mg FDC QD + SOF 400 mg QD G3 G1 Noncirrhot c C-SWIFT: Grazoprevir)+ Elbasvir) + SOF in untreated G1 pts with/without cirrhosis, for 4, 6, or 8 weeks Cirrhot c Noncirrhotc Cirrhotc D1 n=31 n=30 n=20 n=21 n=20 n=15 n=10 TW4 TW8 TW12 G1a 76 87% Viral load >6 million IU/mL in 17 19% non-cirrhotcs and 0 5% in cirrhotcs Primary endpoint: SVR12 SVR4/8 (%) ,7 Non-cirrhotc 86,7 80 Cirrhotc 94,7 4 wks 6 wks 6 wks 8 wks 12/31 26/30 16/20 18/19 Lawitz E, et al. AASLD 2014, Boston. #LB-33
24 Short Duraton Therapy Some patents respond Some patents don t respond
25 Short Duraton Therapy Some patents respond Some patents don t respond Can we predict who will respond and who won t?
26 C-SWIFT: Grazoprevir)+ Elbasvir) + SOF in untreated G1 pts with/without cirrhosis, for 4, 6, or 8 weeks High viral load and non CC predictve of failure with 4- week duraton Lawitz E, et al. AASLD 2014, Boston. #LB-33
27 Short Duraton Therapy Response Guided Therapy? With Peg/Riba response guided therapy was popular and effectve With all oral regimes most patents are negatve after 4 weeks
28 Response Guided Therapy All-Oral Triple-DAA regimens 26 non-cirrhotc Chinese patents (G1b) Response-guided therapy: RVR (= HCV RNA <500 IU/mL by Day 2): Tx duraton 3 weeks Non-RVR: Tx duraton 8 12 weeks Group / Tx regimen RVR SVR 1: SOF, LDV, ASV (n=12) 6/12 6/6 2: SOF, DCV, SMV (n=6) 6/6 6/6 3: SOF, DCV, ASV (n=8) 6/8 6/6 Patents <500 IU/ml by day 3 had 100% SVR after 3 weeks therapy Lau GK, et al. AASLD 2015, San Francisco. #LB-23
29 Factors influencing SVR in English EAP Univariate Multvariate Odds rato 95% CI Odds rato Treatment Sof/DCV/Riba Ref Ref 95% CI Sof/LDV/Riba * Without Riba * Genotype Type 1 Ref Ref Type * Other Viraemic at 2 weeks? No Ref Ref Yes 2.3* *
30 Factors influencing SVR in English EAP Univariate Multvariate Odds rato 95% CI Odds rato Treatment Sof/DCV/Riba Ref Ref 95% CI Sof/LDV/Riba * Without Riba * Genotype Type 1 Ref Ref Type * Other Viraemic at 2 weeks? No Ref Ref Yes 2.3* * Trial of 24 vs 12 weeks sof/dac/riba in G3 slow responders under way
31 Optmisaton of Therapy The Theory The Practce The costs
32 Resistance Associated Variants (RAVs) may reduce response SVR12 by Y93H or any NS5A RAV and IL28B genotype* With Y93H No Y93H With RAVs No RAVs Pts (%) 74/ / / / / / / / 977 Zeuzem S, et al. AASLD 2015, San Francisco. #91
33 Resistance Associated Variants (RAVs) may reduce response SVR12 by Y93H or any NS5A RAV and IL28B genotype* With Y93H No Y93H With RAVs No RAVs Pts (%) 74/ / / / / / / / 977 Zeuzem S, et al. AASLD 2015, San Francisco. #91
34 Resistance analyses (NS5A) Phase 2/3 studies of LDV/SOF ± RBV Phase 2/3 studies of LDV/SOF ± RBV 2144 G1 patents treated (51 (2.4%) no SVR) Deep sequencing at baseline NS5A RAVs in 16% 92% SVR Deep sequencing at virologic failure (VF) NS5A RAVs in 38 (74.5%) Sarrazin C, et al. AASLD 2014, Boston. #1926 *One baseline NS5A RAV no longer detected at VF
35 Resistance analyses (NS5A) Phase 2/3 studies of LDV/SOF ± RBV Phase 2/3 studies of LDV/SOF ± RBV 2144 G1 patents treated (51 (2.4%) no SVR) Deep sequencing at baseline NS5A RAVs in 16% 92% SVR Deep sequencing at virologic failure (VF) NS5A RAVs in 38 (74.5%) Sarrazin C, et al. AASLD 2014, Boston. #1926 *One baseline NS5A RAV no longer detected at VF
36 Resistance analyses (NS5A) Phase 2/3 studies of LDV/SOF ± RBV Phase 2/3 studies of LDV/SOF ± RBV 2144 G1 patents treated (51 (2.4%) no SVR) Deep sequencing at baseline NS5A RAVs in 16% 92% SVR Deep sequencing at virologic failure (VF) NS5A RAVs in 38 (74.5%) Resistance analysis in patents with Virologic Failure Subjects with NS5A RAVs n (%) Variants G1a G1b Total G1 (n=42) (n=9) (n=51) Present at BL 19 (45.2) 3 (33.3) 22 (43.0) Present at VF 30 (71.4) 8 (88.9) 38 (74.5)* Sarrazin C, et al. AASLD 2014, Boston. #1926 *One baseline NS5A RAV no longer detected at VF
37 RAVs Associated with failure More common post therapy in treatment failures Will short course therapy generate resistance?
38 102 G1 ± cirrhosis treated with grazoprevir 100 mg/elbasvir 50 mg FDC QD + SOF 400 mg QD G3 G1 Noncirrhot c C-SWIFT: Grazoprevir)+ Elbasvir) + SOF in untreated G1 pts with/without cirrhosis, for 4, 6, or 8 weeks Cirrhot c Noncirrhotc Cirrhotc D1 n=31 n=30 n=20 n=21 n=20 n=15 n=10 TW4 TW8 TW12 G1a 76 87% Viral load >6 million IU/mL in 17 19% non-cirrhotcs and 0 5% in cirrhotcs Primary endpoint: SVR12 SVR4/8 (%) ,7 Non-cirrhotc 86,7 80 Cirrhotc 94,7 4 wks 6 wks 6 wks 8 wks 12/31 26/30 16/20 18/19 Lawitz E, et al. AASLD 2014, Boston. #LB-33
39 C-SWIFT retreatment : 12 weeks of EBR/GZR + SOF + RBV successfully treated G1-infected subjects who failed shortduraton all-oral therapy SVR /* 23 18/ 18 5/ 5 15/ 15 8/ 8 5/ 5 18/ 18 Cirrhosis Prior Tx duraton Baseline NS5A RAVs *Excludes 2 patents LTFU at Day 3 and treatment Week 4 Lawitz E, et al. AASLD 2015, San Francisco. #LB-12
40 RAVs Might be less problematc in patents treated with short courses BUT Lengthy re-treatment needed
41 Individual Optmisaton of Therapy Theory Short course therapy with extended therapy for failures may be cost-effectve Careful selecton of patents will be critcal Robust re-treatment regimens will be necessary Studies in the UK are on-going
42 Individual Optmisaton of Therapy Physicians Response?
43 Individual Optmisaton of Therapy Physicians Response?
What is the Optimized Treatment Duration? To Overtreat versus Undertreat. Nancy Reau, MD Associate Professor of Medicine University of Chicago
What is the Optimized Treatment Duration? To Overtreat versus Undertreat Nancy Reau, MD Associate Professor of Medicine University of Chicago Learning Objectives: 1. Discuss patient populations appropriate
HCV In 2015: Maximizing SVR
HCV In 2015: Maximizing SVR Alnoor Ramji Gastroenterology & Hepatology Clinical Associate Professor Division of Gastroenterology University Of British Columbia ramji_a@hotmail.com Disclosures (within Last
Genotype 1 HCV in 2016: Clinical Decision Making in a Time of Plenty
Genotype 1 HCV in 216: Clinical Decision Making in a Time of Plenty Ira M. Jacobson, MD Chair, Department of Medicine Mount Sinai Beth Israel Senior Faculty and Vice-Chair, Department of Medicine Icahn
Hepa%%s C elimina%on needs involvement of all turn the page. Graham R Foster Professor of Hepatology Queen Mary University of London
Hepa%%s C elimina%on needs involvement of all turn the page Graham R Foster Professor of Hepatology Queen Mary University of London Conflicts of Interest Speaker and consultancy fees received from AbbVie,
Baseline and acquired viral resistance to DAAs: how to test and manage
Baseline and acquired viral resistance to DAAs: how to test and manage Round table discussion by Marc Bourliere, Robert Flisiak, Vasily Isakov, Mark Sulkowsky & Konstantin Zhdanov Prevalence of baseline
Treatment of HCV in 2016
5/1/16 Treatment of HCV in 16 Graham R Foster Professor of Hepatology QMUL Conflicts of Interest Speaker and consultancy fees received from AbbVie, BI, BMS, Gilead, Janssen, Roche, Merck, Novartis, Springbank,
IFN-free therapy in naïve HCV GT1 patients
IFN-free therapy in naïve HCV GT1 patients Paris Hepatitis Conference Paris, 12th January, 2015 Pr Tarik Asselah MD, PhD; Service d Hépatologie & INSERM U773 University Paris Diderot, Hôpital Beaujon,
Why make this statement?
HCV Council 2014 10 clinical practice statements were evaluated by the Council A review of the available literature was conducted The level of support and level of evidence for the statements were discussed
Treatment of HCV infection in daily clinical practice. Which are the optimal options for Genotypes 2 and 3? Jiannis Vlachogiannakos
Treatment of HCV infection in daily clinical practice. Which are the optimal options for Genotypes 2 and 3? Jiannis Vlachogiannakos Associate Professor of Gastroenterology Academic Department of Gastroenterology
STATE OF THE ART Update: Treatment Options 2016 Mark Sulkowski, MD
Housekeeping Please turn off or silence cell phones. Restrooms are located on this floor. Make a left out of the ballroom foyer and the men s room is on your left. The ladies room is across from the elevators
Pivotal New England Journal of Medicine papers 2014 Phase 3 Trial data
4 th HCV Therapy Advances Meeting Paris, December 12-13, 14 Pivotal New England Journal of Medicine papers 14 Phase 3 Trial data Stefan Zeuzem, MD University of Frankfurt Germany Disclosures Consultancies:
HCV Treatment Failure: What Next? Dr Ashley Brown, Imperial College Healthcare NHS Trust, London
HCV Treatment Failure: What Next? Dr Ashley Brown, Imperial College Healthcare NHS Trust, London European HIV Hepatitis Co-infection Conference QEII Conference Centre 10 th December 2015 Dr Ashley Brown
Hepatitis C in Special Populations
Hepatitis C in Special Populations David E. Bernstein, MD, FACG Vice Chairman of Medicine for Clinical Trials Chief, Division of Hepatology and Sandra Atlas Bass Center for Liver Diseases Northwell Health
Latest Treatment Updates for GT 2 and GT 3 Patients
Latest Treatment Updates for GT 2 and GT 3 Patients Eric Lawitz, MD, AGAF, CPI Vice President, Scientific and Research Development The Texas Liver Institute Clinical Professor of Medicine University of
5/12/2016. Learning Objectives. Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients
5/12/216 Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients Alexander Monto, MD Professor of Clinical Medicine University of California San Francisco San Francisco,
NS5A inhibitors: ideal candidates for combination?
NS5A inhibitors: ideal candidates for combination? Professor Vasily Isakov, MD, PhD, AGAF Dep.Gastroentrology & Hepatology, ION, Russian Academy of Sciences, Moscow Structure and function of NS5A Meigang
HCV Resistance Clinical Aspects. Sanjay Bhagani Royal Free Hospital/UCL London
HCV Resistance Clinical Aspects Sanjay Bhagani Royal Free Hospital/UCL London DAAs in 2018, and beyond % patients % patients Changing characteristics of patients treated with DAA over time Prospective,
Initial Treatment of HCV G Hugo E. Vargas, MD Professor of Medicine Medical, Director Office of Clinical Research Mayo Clinic Arizona
Initial Treatment of HCV G1 2016 Hugo E. Vargas, MD Professor of Medicine Medical, Director Office of Clinical Research Mayo Clinic Arizona Disclosure Information Disclosure Information Dr. Vargas receives
VII CURSO AVANCES EN INFECCIÓN VIH Y HEPATITIS VIRALES
VII CURSO AVANCES EN INFECCIÓN VIH Y HEPATITIS VIRALES REGIMENES TERAPÊUTICOS DE LA HEPATITIS C, INTERFERÓN FREE A Coruña 2 Febrero 2013 Rui Sarmento e Castro Centro Hospitalar do Porto HJU ECS Universidade
Clinical Management: Treatment of HCV Mono-infection
Clinical Management: Treatment of HCV Mono-infection Curtis Cooper, MD, FRCPC Associate Professor-University of Ottawa The Ottawa Hospital- Infections Diseases Viral Hepatitis Program- Director Industry
10/21/2016. Susanna Naggie, MD, MHS Associate Professor of Medicine Duke University Durham, North Carolina. Learning Objectives
A Crash Course on the AASLD/IDSA Hepatitis C Virus Infection Treatment Guidelines: What s New Susanna Naggie, MD, MHS Associate Professor of Medicine Duke University Durham, North Carolina FORMATTED: 1/3/16
Saeed Hamid, MD Alex Thompson, MD, PhD
Saeed Hamid, MD Alex Thompson, MD, PhD 1 We will review some top line data from EASL Majority of the time discussing how the data affects daily practice 2 Grazoprevir (GZR; MK-5172) + Elbasvir (EBR; MK-
Direct-acting Antiviral (DAA) Regimens in Late-stage Development: Which Patients Should Wait? Fred Poordad, MD
Direct-acting Antiviral (DAA) Regimens in Late-stage Development: Which Patients Should Wait? Fred Poordad, MD The HCV Lifecycle: Multiple Targets Polymerase Inhibitors Protease Inhibitors NS5A Inhibitors
HCV Infection: EASL Clinical Practice Guidelines Francesco Negro University Hospital Geneva Switzerland
HCV Infection: EASL Clinical Practice Guidelines 2016 Francesco Negro University Hospital Geneva Switzerland Panel Codinat: Jean-Michel Pawlotsky Panel: Alessio Aghemo David Back Geoffrey Dusheiko Xavier
Treatment of Unique Populations Raymond T. Chung, MD
Treatment of Unique Populations Raymond T. Chung, MD Director of Hepatology and Liver Center Vice Chief, Gastroenterology Kevin and Polly Maroni Research Scholar Mass General Hospital Disclosures Research
10/21/2016. David L. Wyles, MD Chief, Division of Infectious Disease Denver Health Medical Center Denver, Colorado
Drug Resistance-Associated Variants in Hepatitis C Virus Infection: Hype or Help? David L. Wyles, MD Chief, Division of Infectious Disease Denver Health Medical Center Denver, Colorado FORMATTED: 1/3/16
Expert Perspectives: Best of HCV from EASL 2015
Best of HCV from EASL 2015 Expert Perspectives: Best of HCV from EASL 2015 Saeed Hamid, MD Alex Thompson, MD, PhD This activity is supported by educational grants from AbbVie, Bristol-Myers Squibb, and
HCV Treatment of Genotype 1: Now and in the Future
HCV Treatment of Genotype 1: Now and in the Future Bruce R. Bacon, MD, FACG James F. King, MD Endowed Chair in Gastroenterology Professor of Internal Medicine Co-Director of the Abdominal Transplant Program
Failure after treatment with DAAs: What to do? Marseille France 2-3 th June 2016
Failure after treatment with DAAs: What to do? Marc Bourliere, MD White Nights of Hepatology Hôpital Saint Joseph Saint Petersburg Marseille France 2-3 th June 16 Disclosures Board member for : Schering-Plough,
Future strategies with new DAAs
Future strategies with new DAAs Ola Weiland professor New direct antiviral drugs Case no 1 male with genotype 2b Male with gt 2b chronic HCV Male with gt 2b relapse afer peg-ifn + RBV during 24 weeks
VIRAL LIVER DISEASE. OAG Post DDW Course Westin Prince, Toronto, June 13-14, 2015
VIRAL LIVER DISEASE OAG Post DDW Course Westin Prince, Toronto, June 13-14, 2015 Financial Interest Disclosure (over the past 24 months) Dr. Paul Marotta Relationships related to this presentation! Research
Interferon free therapy Are we getting there? Graham R Foster Queen Marys University of London
Interferon free therapy Are we getting there? Graham R Foster Queen Marys University of London IFN free therapy Disclosures I have received personal and institutional funding from companies that sell drug
IFN-free for Genotype 1 HCV: the current landscape. Prof. Graham R Foster
IFN-free for Genotype 1 HCV: the current landscape Prof. Graham R Foster Wonderful new drugs are coming Poordad F, et al. New Engl J Med 2014; online DOI: 10.1056/NEJMoa1402869. 2 The New Drugs Two treatment
A One-day Scientific Conference: Updates on Hepatitis C Treatments along with Consensus on Management of Hepatitis C in Iran
A One-day Scientific Conference: Updates on Hepatitis C Treatments along with Consensus on Management of Hepatitis C in Iran Teheran, 22 July 2016 Massimo Colombo Treatment of HCV genotype 1 & 4 with DAAs
Introduction. The ELECTRON Trial
63rd AASLD November 9-13, 12 Boston, Massachusetts Faculty Douglas T. Dieterich, MD Professor of Medicine and Director of CME Department of Medicine Director of Outpatient Hepatology Division of Liver
HCV: The next 18 months. David L. Wyles, M.D. Associate Professor of Medicine UCSD
HCV: The next 18 months David L. Wyles, M.D. Associate Professor of Medicine UCSD FIRST, A LOOK BACK WHAT DID I SAY LAST YEAR? My predictions for genotype 1: Multiple highly efficacious, well-tolerated,
HCV Update from AASLD 2016
HCV Update from AASLD 2016 Ahmed Elsharkawy Consultant Hepatologist QE Birmingham Secretary and Chair-Elect of BVHG BHIVA/BVHG Feedback Meeting November 2016 Speaker Name Ahmed Elsharkawy Statement Speaking
Case 4: A 61-year-old man with HCV genotype 3 with cirrhosis. Ira M. Jacobson, M.D. Weill Cornell Medical College New York, New York USA
Case 4: A 61-year-old man with HCV genotype 3 with cirrhosis Ira M. Jacobson, M.D. Weill Cornell Medical College New York, New York USA 1 Genotype 3 case 61-year-old man with HCV genotype 3 Cirrhosis on
TREATMENT OF GENOTYPE 2
Treatment of Genotype 2, 3,and 4 David E. Bernstein, MD, FACG Advisory Committee/Board Member: AbbVie Pharmaceuticals, Gilead, Merck, Janssen Consultant: AbbVie Pharmaceuticals, Bristol-Myers Squibb, Gilead,
Personalised Treatment with Telaprevir in Graham R Foster Professor of Hepatology Queen Marys University of London
Personalised Treatment with Telaprevir in 2014 Graham R Foster Professor of Hepatology Queen Marys University of London Telaprevir in 2014 Disclaimers I have received funds from: BI, BMS, Janssen, Novarts,
David L. Wyles, MD Chief, Division of Infectious Disease Denver Health Medical Center Denver, Colorado
FORMATTED: 1/3/16 Drug Resistance-Associated Variants in Hepatitis C Virus Infection: Hype or Help? Atlanta, Georgia: October 2, 216 David L. Wyles, MD Chief, Division of Infectious Disease Denver Health
Rapid Response from San Francisco: The Latest in the HCV Treatment Revolution
Activity presentations are considered intellectual property. These slides may not be published or posted online without permission from Vindico Medical Education (cme@vindicocme.com). Please be respectful
Is HCV drug resistance an issue?
Is HCV drug resistance an issue? 5TH ASIAN CONFERENCE ON HEPATITIS&AIDS NANJING, CHINA 28-29 MAY 2016 FROM BASIC SCIENCE TO CLINICAL PRACTIC Jürgen Kurt Rockstroh Department of Medicine I, University Hospital
Hepatitis C: New Therapies in
Hepatitis C: New Therapies in 216-217 Mark Sulkowski, MD Professor of Medicine Johns Hopkins University School of Medicine Medical Director, Viral Hepatitis Center Divisions of Infectious Diseases and
Update on the Treatment of HCV
Update on the Treatment of HCV K. Rajender Reddy, MD Professor of Medicine Director of Hepatology Director, Viral Hepatitis Center University of Pennsylvania Philadelphia, USA 1 K. Rajender Reddy, MD Disclosure
Treatment of hepatitis C today and tomorrow Antonio Craxì GI & Liver Unit, Di.Bi.M.I.S., University of Palermo, Italy
Treatment of hepatitis C today and tomorrow Antonio Craxì GI & Liver Unit, Di.Bi.M.I.S., University of Palermo, Italy antonio.craxi@unipa.it Ad Board and grants: Abbvie, Achillion, BristolMyers Squibb,
Treatments of Genotype 2, 3,and 4: Now and in the future
Treatments of Genotype 2, 3,and 4: Now and in the future THERAPY FOR THE TREATMENT OF GENOTYPE 2 1 GT 2 and GT 3 Treatment-Naïve: SOF+RBV vs PEG-IFN+RBV FISSION Study Design HCV GT 2 and GT 3 Treatment-naïve
Update in the Management of Hepatitis C: What Does the Future Hold
Update in the Management of Hepatitis C: What Does the Future Hold Paul Y Kwo, MD, FACG Professor of Medicine Mdi Medical ldirector, Liver Transplantation tti Gastroenterology/Hepatology Division Indiana
Evolution of Therapy in HCV
Hepatitis C: Update on New Therapies and AASLD 13 David Bernstein, MD, FACP, AGAF, FACP Professor of Medicine Hofstra North Shore-LIJ School of Medicine Evolution of Therapy in HCV 199 1999 1 13 (%) SVR
What do we need to know about RAVs clinically?
14 th European HIV & Hepatitis Workshop Rome, 25-27 May, 2016 What do we need to know about RAVs clinically? Stefan Zeuzem, MD University of Frankfurt Germany Background Resistance associated variants
Debate: Do We Need More HCV Drugs Con Standpoint
Debate: Do We Need More HCV Drugs Con Standpoint 18 th Antivirals PK Workshop, Friday 16 th June 2017, Chicago Jürgen Rockstroh Department of Medicine I University Hospital Bonn, Bonn, Germany Conflict
Cases: Management of Hepatitis C in Prior Treatment Failure
Cases: Management of Hepatitis C in Prior Treatment Failure David L. Wyles, MD Professor of Medicine University of Colorado Chief, Division of Infectious Disease Denver Health Learning Objectives After
Learning Objective. After completing this educational activity, participants should be able to:
Learning Objective After completing this educational activity, participants should be able to: Use patient characteristics and preferences to select HCV treatment strategies that maximize the potential
Ari Bunim, M.D. Director of Hepatology New York Hospital Queens Assistant Professor of Clinical Medicine Weill Cornell Medical College
Ari Bunim, M.D. Director of Hepatology New York Hospital Queens Assistant Professor of Clinical Medicine Weill Cornell Medical College New York State Law Goes into Effect January 1, 2014 Hepatitis C Virus
How to optimize treatment in G3 patients? Jérôme GOURNAY, MD Hépatologie Centre Hospitalier Universitaire de Nantes France
How to optimize treatment in G3 patients? Jérôme GOURNAY, MD Hépatologie Centre Hospitalier Universitaire de Nantes France Paris Hepatitis Conference, January 12, 2016 Disclosures I have received funding
ICVH 2016 Oral Presentation: 28
Ledipasvir/Sofosbuvir Is Safe and Effective for the Treatment of Patients with Genotype 1 Chronic HCV Infection in Both HCV Mono- and HIV/HCV Coinfected Patients A Luetkemeyer 1, C Cooper 2, P Kwo 3, K
Viva La Revolución: Options to Combat Hepatitis C
Viva La Revolución: Options to Combat Hepatitis C David L. Wyles, MD Professor of Medicine University of Colorado Chief, Division of Infectious Disease Denver Health Learning Objectives After attending
2017 Bruce Lucas Hepatology and Liver Transplant Symposium October 13th 2017 Management of Hepatitis C in Pre- and Post-Transplant Patients
2017 Bruce Lucas Hepatology and Liver Transplant Symposium October 13th 2017 Management of Hepatitis C in Pre- and Post-Transplant Patients Jens Rosenau, MD Associate Professor of Medicine Acting Director
Hepatitis C Treatment 2014
Hepatitis C Treatment 214 Brendan M. McGuire, MD UAB Liver Center Outline Epidemiology/National History Terminology for Treatment Treatment Considerations Current Treatment Options Genotype 1 (GT 1) Genotype
Update on chronic hepatitis C treatment: current trends, new challenges, what next?
Update on chronic hepatitis C treatment: current trends, new challenges, what next? Matti Maimets 12.06.2015 MMaimets15 Disclosure this presentation is sponsored by Gilead Sciences MMaimets15 MMaimets15
Highlights of AASLD 2012 CCO Official Conference Coverage of the 2012 Annual Meeting of the American Association for the Study of Liver Diseases
Highlights of AASLD 12 CCO Official Conference Coverage of the 12 Annual Meeting of the American Association for the Study of Liver Diseases November 9-13, 12 Boston, Massachusetts In partnership with
Antiviral treatment in HCV cirrhotic patients on waiting list
Antiviral treatment in HCV cirrhotic patients on waiting list Krzysztof Tomasiewicz Department of Hepatology and Infectious Diseases Medical University of Lublin, Poland Disclosures Consultancy/Advisory
Study Design - GT 1 Retreatment
Retreatment of Patients Who Failed 8 or 12 Weeks of Ledipasvir/Sofosbuvir-Based Regimens With Ledipasvir/Sofosbuvir for 24 Weeks Eric Lawitz, Steven Flamm, Jenny C. Yang, Phillip S. Pang, Yanni Zhu, Evguenia
CCO Official Conference Coverage: Clinical Impact of New Data From AASLD 2015
CCO Official Conference Coverage: Clinical Impact of New Data From AASLD 2015 CCO Official Conference Coverage of the 2015 Annual Meeting of the American Association for the Study of Liver Diseases, November
Rome, February nd Riunione Annuale AISF th AISF ANNUAL MEETING
Rome, February 20-21 nd 2014 Riunione Annuale AISF 2014 14 th AISF ANNUAL MEETING Present and future treatment strategies for patients with HCV infection: chronic hepatitis and special populations IFN
Minimizing treatment duration and doses
Minimizing treatment duration and doses Jordan J. Feld MD MPH Toronto Centre for Liver Disease Sandra Rotman Centre for Global Health University of Toronto Disclosures Research: Abbvie, Gilead, Janssen,
New Therapeutic Strategies: Polymerase Inhibitors
New Therapeutic Strategies: Polymerase Inhibitors 6th Paris Hepatitis Conference 14 th - 15 th January, 2013 Stefan Zeuzem Goethe University Hospital Frankfurt, Germany Direct antiviral targets C E1 E2
Case 2: A 71-year-old man with cirrhosis
Case 2: A 71-year-old man with cirrhosis 1 JM, 71 year old African American male with known cirrhosis Asymptomatic apart from fatigue No prior history of decompensation Past history: Diabetes for 11 years
THE LIVER MEETING 2014:
THE LIVER MEETING 2014: Summary of presentations from the 65 th Annual Liver Meeting of the American Association for the of Liver Diseases (AASLD), held in Boston, Massachusetts, USA, on 7 th -11 th November
Shorter Durations and Pan-genotypic Regimens The Final Frontier. Professor Greg Dore
Shorter Durations and Pan-genotypic Regimens The Final Frontier Professor Greg Dore Disclosures Funding and speaker fees from AbbVie, Bristol-Myers Squibb, Gilead Sciences and Merck Efficacy Evolution
Hepatitis C: Difficult-to-treat Patients 11th Paris Hepatology Conference 16th January 2018 Stefan Zeuzem, MD University Hospital, Frankfurt, Germany
Hepatitis C: Difficult-to-treat Patients 11th Paris Hepatology Conference 16th January 2018 Stefan Zeuzem, MD University Hospital, Frankfurt, Germany PHC 2018 - www.aphc.info Disclosures Advisory boards:
The HCV Pipeline Ira M. Jacobson, MD, FACP, FACG, AGAF. Slide Presentation. IFN-free DAA combinations (G1)
Slide Presentation The HCV Pipeline Vincent Astor Distinguished Professor of Medicine Chief, Division of Gastroenterology and Hepatology Medical Director, Center for the Study of Hepatitis C Weill Cornell
8/5/2014. A new era of HCV clinical management. Direct-Acting Antivirals for Hepatitis C. Goal of HCV treatment is viral cure HIV HBV HCV
NS5B NS5B 8/5/214 A new era of HCV clinical management Mark Sulkowski, MD Professor of Medicine Medical Director, Viral Hepatitis Center Divisions of Infectious Disease and Gastroenterology/Hepatology
Management of HCV in Prior Treatment Failure
Management of HCV in Prior Treatment Failure Arthur Y. Kim, MD Associate Professor of Medicine Harvard Medical School Boston, Massachusetts Learning Objectives After attending this presentation, learners
Ledipasvir-Sofosbuvir (Harvoni)
HEPATITIS WEB STUDY HEPATITIS C ONLINE Ledipasvir-Sofosbuvir (Harvoni) Robert G. Gish MD Professor, Consultant, Stanford University Medical Center Senior Medical Director, St Josephs Hospital and Medical
Treatement Experienced patients without cirrhosis. Rafael Esteban Hospital Universitario Valle Hebron Barcelona
Treatement Experienced patients without cirrhosis Rafael Esteban Hospital Universitario Valle Hebron Barcelona Agenda With IFN PegIFN+ Ribavirin + Simeprevir PegIFN+ Ribavirin+ Sofosbuvir Without IFN Sofosbuvir
New developments in HCV research and their implications for front-line practice
New developments in HCV research and their implications for front-line practice Dr. Curtis Cooper Associate Professor, University of Ottawa Director, Ottawa Hospital Viral Hepatitis Program June 17, 2013
EASL 2013 Interferon Free, All Oral Regimens for Hepatitis C. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain
EASL 2013 Interferon Free, All Oral Regimens for Hepatitis C Maria Buti Hospital Universitario Valle Hebron Barcelona Spain The first Results with Oral therapy: a Protease Inhibitor and NS5A inhibitor
Associate Professor of Medicine University of Chicago
Nancy Reau, MD Associate Professor of Medicine University of Chicago Management of Hepatitis C: New Drugs and New Paradigms HCV is More Lethal than HIV Infection HCV superseded HIV as a cause of death
Identifying Subgroups in Product Labeling: 2 Recent Case Studies. Martin King AbbVie
Identifying Subgroups in Product Labeling: 2 Recent Case Studies Martin King AbbVie Disclosures The presentation was sponsored by AbbVie. AbbVie contributed to the design, research, and interpretation
A treatment revolution: current management for chronic HCV
A treatment revolution: current management for chronic HCV Ray Chung, M.D. Director of Hepatology and Liver Center Kevin and Polly Maroni Research Scholar Massachusetts General Hospital Disclosures Research
SVR Updates from the 2013 EASL
Updates from the 2013 EASL By Tracy Swan, Treatment Action Group Streamlining HCV Treatment Treatment for hepatitis C virus (HCV) is becoming simpler, shorter, and more effective. All-oral combinations
Treating now vs. post transplant
Resistance with treatment failure Treating now vs. post transplant Pros (for treating pre transplant) If SVR efficacy means Better quality of life Removal from waiting list No post transplant recurrence
HCV Management in Decompensated Cirrhosis: Current Therapies
Treatment of Patients with Decompensated Cirrhosis and Liver Transplant Recipients Paul Y. Kwo, MD, FACG Professor of Medicine Gastroenterology/Hepatology Division Stanford University email pkwo@stanford.edu
Need to Assess HCV Resistance to DAAs: Is it Useful and When?
Need to Assess HCV Resistance to DAAs: Is it Useful and When? Stéphane Chevaliez French National Reference Center for Viral Hepatitis B, C and delta Department of Virology & INSERM U955 Henri Mondor Hospital
What Should We Do With Difficult to Treat HCV Populations?
What Should We Do With Difficult to Treat HCV Populations? Norah Terrault, MD Professor of Medicine and Surgery Director, Viral Hepatitis Center University of California San Francisco Disclosures Norah
Will difficult-to-treat patients remain difficultto-treat. generation of treatments?
Will difficult-to-treat patients remain difficultto-treat with the new generation of treatments? Jordan J Feld MD MPH Toronto Centre for Liver Disease Sandra Rotman Centre for Global Health University
HCV Resistance Associated variants: impact on chronic hepatitis C treatment
HCV Resistance Associated variants: impact on chronic hepatitis C treatment Dr. Stéphane Chevaliez Associate Professor of Medicine at the University of Paris-Est. History of Resistance in HCV Concern Only
Virological tools for hepatitis C: re-treatment and resistance. Joop Arends Will Irving. by author
Virological tools for hepatitis C: re-treatment and resistance Joop Arends Will Irving Disclosures Joop Arends Advisory board: Gilead, Abbvie, Janssen, MSD, BMS (research) grants: Abbvie, BMS, MSD and
Phase 3. Treatment Experienced. Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2. Afdhal N, et al. N Engl J Med. 2014;370:
Phase 3 Treatment Experienced Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2 Afdhal N, et al. N Engl J Med. 2014;370:1483-93. Ledipasvir-Sofosbuvir +/- Ribavirin in Treatment-Experienced HCV
HIV-HCV coinfection. Mark Sulkowski, MD Professor of Medicine Johns Hopkins University School of Medicine Baltimore, Maryland
HIV-HCV coinfection Mark Sulkowski, MD Professor of Medicine Johns Hopkins University School of Medicine Baltimore, Maryland Disclosures Principal investigator for research grants Funds paid to Johns Hopkins
HCV Treatment Options in 2017/2018: What s Here and What s Coming Soon
HCV Treatment Options in 2017/2018: What s Here and What s Coming Soon Supported by educational grants from AbbVie; Bristol-Myers Squibb; Gilead Sciences; Janssen Therapeutics; Merck & Co., Inc; and ViiV
Disclosures. Advanced HCV management. Overview. Renal failure 1/10/2018. Research Grant support to UCSF from AbbVie Gilead Merck Proteus NIH
Disclosures Advanced HCV management Annie Luetkemeyer, MD Division of HIV, ID and Global Medicine ZSFG, UCSF Research Grant support to UCSF from AbbVie Gilead Merck Proteus NIH Overview Renal failure Acute
5/10/2016. Management of Hepatitis C Virus Genotype 1 and 4 Treatment-Naive and Treatment-Experienced Patients. HCV life-cycle and antiviral targets
5/1/216 Management of Hepatitis C Virus Genotype 1 and 4 Treatment-Naive and Treatment-Experienced Patients David L. Wyles, MD Associate Professor of Medicine University of California San Diego La Jolla,
Feeling right at home
Feeling right at home Getting to Cure From Cure to Eradication Jordan J. Feld MD MPH Toronto Centre for Liver Disease Sandra Rotman Centre for Global Health University of Toronto SVR Dramatic Improvements
Hepatitis C Resistance Associated Variants (RAVs)
Hepatitis C Resistance Associated Variants (RAVs) Atif Zaman, MD MPH Oregon Health & Science University Professor of Medicine Division of Gastroenterology and Hepatology Nothing to disclose Disclosure
Hepatitis C: Newest Treatment Options and What To Do When We Cure It!
Hepatitis C: Newest Treatment Options and What To Do When We Cure It! Richard Kalman, MD Division of Hepatology Department of Transplantation Einstein Medical Center Learning Objectives Scope of HCV How
New Hepatitis C Antivirals
New Hepatitis C Antivirals Kris Stewart, BSP, MD, FRCPC Drug Therapy Conference College of Medicine, University of Saskatchewan September 23, 2016 Disclosures I have received research and program support
HCV-G3: Sofosbuvir with ledipasvir or daclatasvir?
HCV-G3: Sofosbuvir with ledipasvir or daclatasvir? Ioannis Goulis, MD Aristotelian University of Thessaloniki XXIII International Hepatitis B & C Meeting of Athens Hadziyannis HCV genotype 3 therapy Chronic